Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03604497 · ClinicalTrials.gov registry record · NA

Using Bluetooth Beacon Technology to Reduce Distracted Pedestrian Behavior

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
437
Enrollment target

NCT03604497: Completed NA study, sponsored by University of Alabama at Birmingham.

NCT03604497 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 437 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03604497, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
437 participants
Enrollment target

Study Summary

Over 4,800 American pedestrians die annually, a figure that is current increasing. One hypothesized reason for the increasing trend in pedestrian injuries and deaths is the role of mobile technology in distracting both pedestrians and drivers. The investigators propose to develop and then evaluate Bluetooth beacon technology as a means to alert and warn pedestrians when they are approaching dangerous intersections, reminding them to attend to the traffic environment and cross the street safely rather than engaging with mobile technology. One aspect of the research will involve a crossover research trial to evaluate efficacy of the program. Bluetooth beacons are very small (about the size of a dime) and inexpensive (\~$20 range) devices that broadcast information unidirectionally (beacon to smartphone) within a closed proximal network. The investigators propose placing beacons at intersection corners (e.g., on signposts) frequently trafficked by urban college students. The beacons will transmit to an app installed on users' smartphones, signaling users to attend to their environment and cross the street safely. The app will be developed to be flexible based on user preferences; for research purposes, the app also will download data concerning the users' behavior while crossing the street. The crossover trial will evaluate the app with a sample of about 411 young adults whose behavior is monitored for: (a) 3 weeks without the app being activated, (b) 3 weeks with the app activated, and then (c) 6 weeks without the app activated to assess retention of behavior. Throughout the 12 week period, the investigators will monitor user behavior at multiple intersections around campus, along with gathering self-report questionnaire perceptions and behavior at baseline and 12-week post-intervention assessments.

Primary Outcome

percentage of street-crossings participants is distracted while crossing streets in intersections involved in the study, as measured electronically by smartphone behavior near those intersections. Electronic measurement was based on x-y-z coordinates of the smartphone during the crossing, as assessed and stored in the participants' phone storage.

Interventions

  • BEHAVIORAL beacon alerts
  • BEHAVIORAL no alerts retention

Trial Details

FieldValue
Enrollment Target 437 participants
Start Date 2019-08-15
Est. Completion 2019-12-21
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the finished NCT03604497 record still lists

NCT03604497 is an interventional study that assigns participants to a tested intervention. The registered 437 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower).

The record links to 0 conditions, and to 2 interventions - of which beacon alerts is the first listed.

NCT03604497 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03604497 about?

NCT03604497 is a clinical study titled "Using Bluetooth Beacon Technology to Reduce Distracted Pedestrian Behavior". Over 4,800 American pedestrians die annually, a figure that is current increasing. One hypothesized reason for the increasing trend in pedestrian injuries and deaths is the role of mobile technology in distracting both pedestrians and drivers. The investigators propose to develop and then evaluate B...

What is the current status of trial NCT03604497?

This trial is currently completed. It is a NA study. The enrollment target is 437 participants. The study started on 2019-08-15. Estimated completion is 2019-12-21.

What interventions are being tested in trial NCT03604497?

The interventions under investigation include: beacon alerts (BEHAVIORAL), no alerts retention (BEHAVIORAL).

Who is sponsoring clinical trial NCT03604497?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03604497's enrollment target sits among peer trials

437 235th of 2000 higher than 1,766 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05711446 · 438 participants · NA

    Double Voiding and Post-transplant UTI

  • NCT02622542 · 436 participants · NA

    ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy

  • NCT05918211 · 436 participants · Phase 3

    Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

  • NCT06966479 · 436 participants · Phase 2

    A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03604497, the US trial registry maintained by the National Library of Medicine. NCT03604497 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.